Breast Cancer Coverage from Every Angle

Kevin Kalinsky, MD, on Clinical Practice Pearls: Updated Results on Endocrine Therapy and Chemotherapy for HR-Positive HER2-Negative Breast Cancer

Posted: Tuesday, January 25, 2022

Kevin Kalinsky, MD, of the Winship Cancer Institute at Emory University, discusses recent phase III findings on the use of chemotherapy and endocrine therapy and how the data may be applied to customize treatment for patients with hormone receptor–positive, HER2-negative breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.